Koninklijke Philips N.V. Earnings Recaps
Q2 2026
Jul 31, 2026
Shares declined 3.1% as investors reacted negatively to a deceleration in order intake amid continued tariff-related margin pressures, despite stable sales growth and maintained full-year guidance.
Key takeaways
- Comparable sales grew 4% in Q2, consistent across all segments.
- Adjusted EBITA margin increased to 16.4%, but underlying margin excluding tariff refunds was 12.2%, highlighting ongoing cost and tariff headwinds.
- Order intake declined 1% overall, with Monitoring orders shifting timing into Q3, interrupting a six-quarter growth streak.
- Continued weakness in China impacted Diagnosis & Treatment orders despite strong growth in North America and Europe.
- Full-year comparable sales growth outlook (3% to 4.5%) and underlying EBITA margin guidance (12.5% to 13%) were reiterated, showing a cautious but stable outlook.
Q1 2026
May 7, 2026
The 3.7% stock gain reflects investor approval of Philips’ solid order intake growth, expanding margins, and clear execution on innovation, despite ongoing macro uncertainties.
Key takeaways
- Order intake rose 6% in Q1, led by equipment growth in Diagnostic & Treatment (D&T) and Connected Care segments.
- Comparable sales increased 4%, driven by broad-based segment contributions and particularly strong personal health performance.
- Adjusted EBITDA margin expanded by 40 basis points to 9%, marking the sixth consecutive quarter of margin improvement despite inflationary pressures such as higher tariffs.
- Innovation momentum remains strong, with 20 FDA 510(k) clearances and premarket approvals—more than doubling year-over-year—including AI-driven solutions in MRI, CT, and Image Guided Therapy.
- North America and Europe sustained leadership in growth, supported by enterprise partnerships and expanded retail distribution channels globally.
Q3 2025
Nov 4, 2025
Royal Philips reported a strong Q3 2025, driven by an 8% growth in order intake and robust performance across all business segments, particularly Personal Health. The company's adjusted EBITDA margin expanded despite ongoing tariff impacts, reflecting effective cost management and innovation.
Key takeaways
- Order intake increased by 8%, marking the fourth consecutive quarter of growth, with strong momentum in North America.
- Comparable sales growth improved to 3% year-on-year, supported by solid demand in Personal Health and Connected Care.
- Adjusted EBITDA margin rose by 50 basis points to 12.3%, showcasing the effectiveness of productivity initiatives.
- The company reiterated its full-year comparable sales growth outlook of 1% to 3%, with a projected adjusted EBITDA margin expected at the upper end of the 11.3% to 11.8% range.
- Free cash flow guidance remains stable at between EUR 0.2 billion and EUR 0.4 billion for the full year.